Beyond Parallel 32

Name

Beyond Parallel 32

Legal name

Beyond Parallel 32

Website

https://beyondparallel32.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Beyond Parallel 32 is a consulting firm exclusively focused on business development, licensing, strategic advisory, and M&A services for pharmaceutical and MedTech companies entering or expanding in Latin America.

Ownership category

akta.pro rank

Product category

Life Science Consulting

NAICS

Management Consulting Services (54161), Other Management Consulting Services (541618)

SIC

Services-Management Consulting Services (8742)

akta.pro primary industry

Industry-Specialist / Sector-Focused M&A Advisory (FSAEAGAJ)

akta.pro secondary industries

M&A Advisory (Buy-Side & Sell-Side) (BPAHAOAA), Cross-Border M&A Advisory (FSAEAGAH), Buy-Side M&A Advisory (FSAEAGAB)

Keywords

• Life science consulting
• Pharmaceutical advisory
• Licensing advisory
• Market entry consulting
• Mergers acquisitions advisory

Headquarters

HQ city

Camden Wyoming

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales

Revenue model

1. Consulting Services: Professional consulting fees for BD & Licensing advisory, strategic consulting, and M&A support services tailored to life science companies operating in or entering Latin America.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Beyond Parallel 32 is a consulting firm exclusively focused on serving life science companies (pharmaceuticals and MedTech) seeking to enter, expand, or optimize operations in Latin America. The firm delivers three integrated service lines: BD & Licensing advisory (opportunity assessment, partner search, due diligence, deal negotiation, and alliance management), strategic consulting (market entry strategy, commercial launch planning, and operational optimization), and M&A advisory (target identification, due diligence, closing support, and post-merger integration).

Product overview

Beyond Parallel 32 is a consulting firm (not a software product company) offering a unified suite of advisory services exclusively focused on life science companies in Latin America. The portfolio consists of three integrated service lines: BD & Licensing Services (covering opportunity assessment, partner search, due diligence, deal negotiation, and alliance management), Consulting Services (market entry, strategy formulation, product launch, and operational optimization for Latin America), and Mergers & Acquisitions Advisory (target identification, M&A due diligence, closing support, and post-merger integration in the region). These services are delivered by a team with expertise across pharmaceuticals and MedTech, serving multinational and regional pharmaceutical companies across 20+ Latin American countries.

Differentiator

Problem solved

Functional benefit

Products and services

• BD & Licensing Services Business Development and Licensing consulting services covering the full deal lifecycle for life science companies in Latin America, including Discovery & Assessment (opportunity sizing, investment evaluation, risk identification), Partnering & Diligence (go-to-market strategy, partner identification, due diligence support), and Closing & Integration (term sheet negotiation, agreement documentation, post-closing project and alliance management). Intended for multinational and regional pharmaceutical and MedTech companies.
• Strategic Consulting Services Strategic consulting for life science companies seeking to enter, expand, or optimize operations in Latin America, including market entry strategy formulation, commercial launch planning, operational optimization, and BD/Alliance Management support. Targeted at life science firms with limited or no Latin American footprint seeking to license or commercialize products in the region.
• Mergers & Acquisitions Advisory M&A advisory services spanning the full transaction lifecycle for life science companies in Latin America: Target Identification (acquisition target sourcing in the region), Due Diligence & Closing (business modeling, assumption validation, negotiation support), and Post Merger Integration (integration planning and execution leadership). Intended for both Big Pharma and startups pursuing acquisitions or transactions in the region.

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• T-HealthcoreStrategic or Co-development PartnerT-Health is a strategic business management consultancy specializing in the healthcare ecosystem in Brazil. They advise companies on strategic planning, structuring, implementation, alignment or business realignment, bringing solutions that transform and enhance results. T-Health appears as a key strategic ally in the Latin America healthcare consulting space.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• ClearView Healthcare Partners: Boutique life sciences strategy consulting firm supporting pharma and biotech on commercial strategy, BD diligence, and market entry. Comparable in size and focus to BP32, though US-centric in core focus.
• T-Health: Strategic business management consultancy focused on the healthcare ecosystem in Brazil. Closest direct peer to BP32, serving the same client base in LATAM with strategic planning and execution support.
• Locust Walk: Boutique life sciences transaction advisory firm specializing in BD, licensing, and M&A advisory for biopharma. Most directly comparable to BP32 in deal-focused life science advisory, though focused on US/global rather than LATAM.

Broad incumbents

• Charles River Associates: Global consulting firm with a life sciences practice that supports pharma strategy, pricing, market access, and commercial diligence. Comparable to BP32 on advisory services for life science clients.
• ZS Associates: Global management consulting firm focused on life sciences with strong commercial and market access expertise. Overlaps with BP32 on strategic consulting and commercial launch advisory for pharma, though serves a global client base.
• IQVIA: Global life sciences consulting and contract research giant with deep LATAM presence. Comparable to BP32 in serving pharma BD, licensing, and market entry advisory at scale, but vastly broader in services and geographies.
• L.E.K. Consulting: Global strategy consulting firm with a dedicated life sciences practice covering pharma, biotech, and MedTech. Comparable to BP32 on commercial strategy, BD advisory, and market entry work, but with broader geographic reach.
• McKinsey & Company: Global management consulting leader with deep pharma and healthcare practice. Competes with BP32 on LATAM pharma strategy, market entry, and M&A advisory at the largest multinational clients.
• Bain & Company: Top-tier global consultancy with a substantial healthcare and life sciences practice that competes on M&A advisory, strategy, and commercial diligence for pharma clients, including LATAM engagements.
• Simon-Kucher & Partners: Global consulting firm known for pricing, market access, and commercial strategy in life sciences. Overlaps with BP32 on pharma commercialization, pricing strategy, and market entry advisory across multiple geographies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/beyond-parallel-32

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Beyond Parallel 32